Gasior Tomasz
Collegium Medicum-Faculty of Medicine, WSB University, 41-300 Dabrowa Gornicza, Poland.
J Clin Med. 2024 Nov 28;13(23):7256. doi: 10.3390/jcm13237256.
Cerebral embolic protection (CEP) during transcatheter aortic valve replacement (TAVR) has emerged as an important tool in reducing stroke risk associated with this intervention. With the recent expansion of TAVR into lower-risk populations, the role of preventive strategies gained greater significance. Despite advancements in TAVR technologies, peri-procedural stroke remains a significant complication, with rates ranging between 2 and 5%. CEP devices, introduced at the time of the procedure, have been developed to capture embolic debris and reduce the risk of neurological events. However, while MRI-detected embolic debris is commonly captured by these devices, the clinical benefit in reducing stroke remains debated. This review provides a comprehensive analysis of recent advances in relevant clinical research and CEP device development, offering recommendations for future studies to improve patient outcomes.
经导管主动脉瓣置换术（TAVR）期间的脑栓塞保护（CEP）已成为降低该干预相关中风风险的重要工具。随着TAVR最近扩展到低风险人群，预防策略的作用变得更加重要。尽管TAVR技术取得了进展，但围手术期中风仍然是一种严重的并发症，发生率在2%至5%之间。在手术时引入的CEP装置已被开发用于捕获栓塞碎片并降低神经事件的风险。然而，虽然这些装置通常能捕获MRI检测到的栓塞碎片，但在降低中风方面的临床益处仍存在争议。本综述对相关临床研究和CEP装置开发的最新进展进行了全面分析，为未来研究提供建议以改善患者预后。
